184 related articles for article (PubMed ID: 17920266)
1. Structure-activity relationship study on the 6-membered heteroaromatic ring system of diphenylpyrazine-type prostacyclin receptor agonists.
Asaki T; Hamamoto T; Sugiyama Y; Kuwano K; Kuwabara K; Niwa T
Bioorg Med Chem Lett; 2007 Dec; 17(23):6588-92. PubMed ID: 17920266
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity studies on diphenylpyrazine derivatives: a novel class of prostacyclin receptor agonists.
Asaki T; Hamamoto T; Sugiyama Y; Kuwano K; Kuwabara K
Bioorg Med Chem; 2007 Nov; 15(21):6692-704. PubMed ID: 17764960
[TBL] [Abstract][Full Text] [Related]
3. Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
Asaki T; Kuwano K; Morrison K; Gatfield J; Hamamoto T; Clozel M
J Med Chem; 2015 Sep; 58(18):7128-37. PubMed ID: 26291199
[TBL] [Abstract][Full Text] [Related]
4. Development of dual-acting benzofurans for thromboxane A2 receptor antagonist and prostacyclin receptor agonist: synthesis, structure-activity relationship, and evaluation of benzofuran derivatives.
Ohno M; Miyamoto M; Hoshi K; Takeda T; Yamada N; Ohtake A
J Med Chem; 2005 Aug; 48(16):5279-94. PubMed ID: 16078846
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist.
Nakamura A; Yamada T; Asaki T
Bioorg Med Chem; 2007 Dec; 15(24):7720-5. PubMed ID: 17881233
[TBL] [Abstract][Full Text] [Related]
6. LIV-3D-QSAR models for PGI2 receptor ligands using multiple conformations.
Azevedo Martins RC; Girão Albuquerque M; Bicca de Alencastro R
Eur J Med Chem; 2004 Apr; 39(4):359-67. PubMed ID: 15072844
[TBL] [Abstract][Full Text] [Related]
7. [PAF-antagonists with phospholipid structure. 3. Phospholipids with heterocyclane head groups and variations of the phosphorus-nitrogen distance; synthesis, characterization and structure-activity relationship].
Kertscher HP; Ostermann G
Pharmazie; 1991 Nov; 46(11):772-4. PubMed ID: 1811226
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of antiplatelet activity of trihydroxychalcone derivatives.
Zhao LM; Jin HS; Sun LP; Piao HR; Quan ZS
Bioorg Med Chem Lett; 2005 Nov; 15(22):5027-9. PubMed ID: 16169724
[TBL] [Abstract][Full Text] [Related]
9. Piperidine derivatives as nonprostanoid IP receptor agonists 2.
Hayashi R; Ito H; Ishigaki T; Morita Y; Miyamoto M; Isogaya M
Bioorg Med Chem Lett; 2016 Jun; 26(12):2886-2889. PubMed ID: 27133594
[TBL] [Abstract][Full Text] [Related]
10. Nonprostanoid prostacyclin mimetics. 5. Structure-activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5- oxazolyl]phenoxy]acetic acid.
Meanwell NA; Romine JL; Rosenfeld MJ; Martin SW; Trehan AK; Wright JJ; Malley MF; Gougoutas JZ; Brassard CL; Buchanan JO
J Med Chem; 1993 Nov; 36(24):3884-903. PubMed ID: 7504734
[TBL] [Abstract][Full Text] [Related]
11. Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists.
Keenan RM; Callahan JF; Samanen JM; Bondinell WE; Calvo RR; Chen L; DeBrosse C; Eggleston DS; Haltiwanger RC; Hwang SM; Jakas DR; Ku TW; Miller WH; Newlander KA; Nichols A; Parker MF; Southhall LS; Uzinskas I; Vasko-Moser JA; Venslavsky JW; Wong AS; Huffman WF
J Med Chem; 1999 Feb; 42(4):545-59. PubMed ID: 10052962
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship between prostacyclin and its platelet receptor. Correlation of structure change and the platelet activity.
Tsai AL; Wu KK
Eicosanoids; 1989; 2(3):131-43. PubMed ID: 2517029
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of adenosines with heterocyclic N6-substituents.
Ashton TD; Aumann KM; Baker SP; Schiesser CH; Scammells PJ
Bioorg Med Chem Lett; 2007 Dec; 17(24):6779-84. PubMed ID: 17967536
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of 2,6-diphenylpyrazine derivatives and their DNA binding and cytotoxic properties.
Dias N; Jacquemard U; Baldeyrou B; Lansiaux A; Goossens JF; Bailly C; Routier S; Mérour JY
Eur J Med Chem; 2005 Dec; 40(12):1206-13. PubMed ID: 16153749
[TBL] [Abstract][Full Text] [Related]
15. Development of 3,4-dihydro-2H-benzo[1,4]oxazine derivatives as dual thromboxane A2 receptor antagonists and prostacyclin receptor agonists.
Ohno M; Tanaka Y; Miyamoto M; Takeda T; Hoshi K; Yamada N; Ohtake A
Bioorg Med Chem; 2006 Mar; 14(6):2005-21. PubMed ID: 16297632
[TBL] [Abstract][Full Text] [Related]
16. Nonprostanoid prostacyclin mimetics. 4. Derivatives of 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid substituted alpha to the oxazole ring.
Meanwell NA; Rosenfeld MJ; Wright JJ; Brassard CL; Buchanan JO; Federici ME; Fleming JS; Gamberdella M; Hartl KS; Zavoico GB
J Med Chem; 1993 Nov; 36(24):3871-83. PubMed ID: 8254619
[TBL] [Abstract][Full Text] [Related]
17. Anti-platelet aggregation activity of some pyrazines.
Ohta A; Takahashi H; Miyata N; Hirono H; Nishio T; Uchino E; Yamada K; Aoyagi Y; Suwabe Y; Fujitake M; Suzuki T; Okamoto K
Biol Pharm Bull; 1997 Oct; 20(10):1076-81. PubMed ID: 9353568
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships for selected sulfur-rich antithrombotic compounds.
MacDonald JA; Langler RF
Biochem Biophys Res Commun; 2000 Jul; 273(2):421-4. PubMed ID: 10873621
[TBL] [Abstract][Full Text] [Related]
19. Novel arylpyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides as platelet aggregation inhibitors. 2. Optimization by quantitative structure-activity relationships.
Campillo N; Goya P; Páez JA
J Med Chem; 1999 Aug; 42(17):3279-88. PubMed ID: 10464014
[TBL] [Abstract][Full Text] [Related]
20. Novel methylene-linked heterocyclic EP1 receptor antagonists.
Hall A; Bit RA; Brown SH; Chowdhury A; Giblin GM; Hurst DN; Kilford IR; Lewell X; Naylor A; Scoccitti T
Bioorg Med Chem Lett; 2008 Mar; 18(5):1592-7. PubMed ID: 18262416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
